当前位置: 首页 > 期刊 > 《中国医学创新》 > 2016年第24期
编号:12954769
Rho激酶抑制剂对急性冠脉综合征患者冠状动脉粥样硬化和血脂水平的影响(4)
http://www.100md.com 2016年8月25日 《中国医学创新》 2016年第24期
     [15] Ishibashi Y,Nakashima S,Matsui T,et al.Rosuvastatin restores advanced glycation end product-induced decrease in sirtuin 1(SIRT1) mRNA levels in THP-1 monocytic cells through its anti-oxidative properties[J].Int J Cardiol,2013,169(6):e102-103.

    [16] Sposito A C,Chapman M J.Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit[J].Arterioscler Thromb Vasc Biol,2002,22(10):1524-1534.

    [17] Nishino M,Hoshida S,Kato H,et al.Preprocedural statin administration can reduce thrombotic reaction after stent implantation[J].Circ J,2008,72(2):232-237.

    [18] Liu P Y,Liu Y W,Lin L J,et al.Evidence for statin pleiotropy in humams: defferiential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity,endothelial function,and inflammation[J].Circulation,2009,119(1):131-138.

    [19] Laufs U,La Fata V,Plutaky J,et al.Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors[J].Circulation,1998,97(12):1129-1135.

    [20] Nohria A,Prsic A,Liu P Y,et al.Statins inhibit Rho kinase activity in patients with atherosclerosis[J].Atherosclerosis,2009,205(2):517-521.

    (收稿日期:2016-01-25) (本文编辑:程旭然), 百拇医药(李文华 何国平 李勇)
上一页1 2 3 4